Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

2017954 citationsJournal Articlebronze Open Access

Authors

Kausik K. Ray · Imperial College London

Ulf Landmesser · Charité - Universitätsmedizin Berlin

Lawrence A. Leiter · University of Toronto

David Kallend · Doctors Company (United States)

Robert Dufour · Montreal Clinical Research Institute

Mahir Karakas · Universität Hamburg

Tim N. Hall

Abstract

In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels. (Funded by the Medicines Company; ORION-1 ClinicalTrials.gov number, NCT02597127 .).

Topics & Keywords

Lipoproteins and Cardiovascular Health Computational Drug Discovery Methods Nuclear Receptors and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 15, pp. 1430-1440

DOI: 10.1056/nejmoa1615758

Field-Weighted Citation Impact: 102.89